Avacta Group Plc

Avacta develops cancer therapies globally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.

It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues AVA7100 that drives localization to fibroblast activation protein expressing tumors. Incorporated in 2003, the company is headquartered in London, the United Kingdom.